Interventional device developer Boston Scientific has received clearance from the U.S. Food and Drug Administration (FDA) for a drug-eluting stent for small vessels, the Natick, MA-based company said.
Taxus Express2 Atom paclitaxel-eluting coronary stent system is designed to treat small coronary vessels, particularly those as small as 2.25 mm in diameter.
The company has also received clearance for Taxus Express2 paclitaxel-eluting coronary stent system for the treatment of in-stent restenosis in bare-metal stents, the first such approval granted by the FDA, according to Boston Scientific.
In other Boston Scientific news, CryoCath Technologies has resolved all outstanding patent suits between itself, its CryoCor subsidiary, and Boston Scientific. The companies have agreed to terminate all court actions involving cryoablation systems in the U.S. and Canada.
Related Reading
Boston Scientific sells off investment portfolio to raise cash, June 19, 2008
Boston Scientific wins FDA clearance for heart failure lead, May 19, 2008
Boston Scientific launches Latitude analysis program, May 16, 2008
Canadian court dismisses J&J lawsuit against Boston Scientific, May 9, 2008
Boston Scientific completes enrollment in MADIT-CRT trial, April 24, 2008
Copyright © 2008 AuntMinnie.com
